Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,171–1,180 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1171
- Medicine slug
- pantoprazole
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 133
- Source count
- 133
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 133
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 133 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58d32be2-166e-1a64-e063-6394a90a26ea (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9e5fac6-2db6-4311-a98b-eb3f0dde19d6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81696241-17d5-4d35-9e59-8c28469ffd2c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03aa46f-9eb5-4cf4-addf-745d94af8261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4494f9d0-a1c8-477f-9b4a-f65d7637d9ec (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:340b57c2-bcf8-4f46-b522-886daaf80351 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bed1bae-519f-1bb9-e063-6294a90a795b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb3f58d4-0c69-4377-be45-c36099c98d33 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d212e8ec-f7ff-4727-a83e-0edc4ca7e6d1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643eb498-d916-4fb7-9281-32895575ab36 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e1839b-7462-4344-b319-001a5f57d67a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb1e79ad-ff52-4696-8743-523f793b29d3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f50bcb-85e5-e3f6-e063-6294a90a11ae (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8748a588-a1e5-9dfc-e053-2a95a90a846c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1680b4ed-d5b0-4fd9-b1d1-04df6a2138be (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e5421ef-0875-4a04-b17d-95cca0052c83 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517d6b02-0e68-4d6b-98b3-eac0be457e6b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1172bc4e-1700-402f-8262-97f05bac0d09 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6faf465b-c3a3-4ae7-9e16-1ba758f6962a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d27e1fdd-e23f-0d60-e053-2a95a90a9087 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02ee7ed6-217f-4128-bbbb-b9390475a65b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9b0d279-118b-4372-bd51-d4bad9c1cfca (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3540d01c-da0e-477e-9e90-994b96deb1d6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e200326-8885-18d0-e063-6294a90aad2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed264262-21bb-1bae-e053-2995a90a8a5e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f85e6d64-1ddc-4f4a-86dc-0749081a6a5f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08098cb2-c048-4640-f387-6beec4a38936 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c286e5c-2b36-422b-9f74-e8c0abb3f747 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cc5197e-6b39-4415-b963-d4bbeecd7953 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17468dbf-84b6-4c53-9ad5-341350d2cfab (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56ad5b97-8e5f-48a5-b2ba-a5484b43d018 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a278de-bd16-417c-a741-81bfe0d745f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e7c1ab-3e75-1ff8-e053-2995a90a7539 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52d5bc28-66df-43aa-bb1a-8ac4a2a7f693 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:014f9762-6948-46b7-8659-5c89f35ad8bf (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b422c5eb-9a6d-4f8c-863d-ca515ec780c2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0696b10c-972b-9dcf-e063-6294a90a1034 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7418f358-f536-4de6-adf0-562b4373f2e3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f2fb647-15bc-41cb-84a4-02e956e614fc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:138b30cb-6b28-450e-9e7a-42576cc76545 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50802e19-72d3-4130-8d14-eb94361b38e7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e102c44-232b-4aaf-b457-2a740c47193a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fbec80c-b38d-122c-e054-00144ff88e88 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9f32edf-e0b9-4e96-e053-2a95a90afbc8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13c337e7-1e7b-47bd-9f88-92b0d548ca9c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4136d983-75fa-9604-e063-6294a90aaac6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9fa8381-b75e-b1cd-e053-2a95a90a9883 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f39b3e7d-39d2-4c8a-9974-4ab885241880 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a1af50-a051-3e55-e053-2a95a90a9184 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5ed424-2203-482f-bb85-2c97d9c356f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:564709e8-358f-c185-4ecb-b3849c3fe59c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbab54-9f11-77bc-e063-6394a90ab449 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5566b4b1-b4f5-4020-e063-6394a90a5257 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c857dc41-7b47-4f26-a9f5-d76eb82b44ee (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bb94d3c-8bc3-4193-9dd8-e9a22066707c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02f3f85-8f9b-4d06-8eae-73e592626f3e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a8fa326-ad75-4b6d-8832-0a2357eeca2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a6b13f-457f-4136-9541-c4adb9c3c35c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9bc288b-e84c-4e31-a769-c87a59226086 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ba4c797-3f97-4d85-971e-7b17bdf89221 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410d5577-e50a-44f3-aaa8-fbf391a0c261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51033ddc-a11a-80fa-e063-6394a90ac54c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549da3e8-f223-2ee7-e063-6394a90a25d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0bb76bc-094a-4d61-9bb2-2226c9da4ae9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e17e4a72-d6a4-4a83-a921-88af9ef028a6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd4759ac-46b5-6903-e053-2a95a90a6319 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924a80b9-de48-90c0-e053-2995a90a00e1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423dac8b-bb1e-4456-9b6e-913c028b11bc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c9e3c6-d4b0-0ebe-e053-2995a90abe55 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ff83f9-7039-ac26-e063-6394a90a37ce (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fcf6a2-3788-4955-84d9-3c319b13267c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:362229c5-7b28-4563-aa62-d97d06005480 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51e4144a-489e-436c-609a-39305f8f56ba (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90963a38-f629-45a4-bddd-9e13a55fe0f7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da67e1c0-9947-957d-e053-2a95a90ad96d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22b71a1d-87f8-43ba-b53d-53ca3f70c63e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0c5dac-6832-4692-b012-ca59d5e88987 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a1159d3-b9fa-4026-962c-d3001002e610 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:558dc7e1-dfd5-d3d7-e063-6394a90ab9c3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bed093a-9586-4c82-a2b7-c68f89d0faef (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c14e2f3-625d-4089-a404-440b0ecf72e7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ff3cf6c-6f0a-4374-8b80-4e1eb1df6245 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1ad8f91-3783-4139-8154-e461a53809c1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6aae78e-308b-7072-e053-2a95a90aaa10 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1eb666a-120d-47fd-8c9f-73cef839294a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7705bf6-e473-4b9c-bb5d-57e26ffe7b97 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aac1642-6cb0-6ad2-e053-2a95a90a4cbd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43fc6326-cfe6-7d1c-e063-6394a90abc24 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6229247e-ee15-466e-a8ac-adcd646b738d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c983da1-a8e0-479e-8816-5d5668ea242e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1f37929-a981-4ace-95e6-ae6795a797b3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f313159c-115a-4cf6-b32e-9ddc833fd51c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3ded82a-cf0d-4844-944a-75f9f9215ff0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485212d4-caee-4a55-8299-87a28d6bd8f0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee6278c0-d8c0-417c-a65c-b522ff76fe44 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f711d8-b9d3-46a6-8bf9-6af1cc77003e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f408cf-1b3e-4d7a-e053-2a95a90a369f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cec41e-e98b-470a-8ba2-c31537023989 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcac4022-fea1-67c5-3331-fefcc3c440d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa8eed8c-f5d0-4b90-b184-cff8d9c8fb6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5331f534-4724-52e8-e063-6394a90aa548 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58c376e-616b-4970-a375-52ff630e7f09 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d03491f-20c6-4878-9741-2e21e221eff2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d51104d-b135-421f-8425-03b5772e7103 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c10e9c12-e39d-4b0b-bd4c-10d3e9a4cf34 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7dc4321-331d-49af-976c-cfd69d0055d9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38353b9e-63bd-47e8-b7cb-b198d1e901f9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2abc159-e450-99dc-e053-2a95a90abe6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:617bb464-5357-472f-8e9d-61aae5b2ebef (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3277cb8-26d0-bce0-e053-2a95a90af6dd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c18aff31-f91e-4b6a-9713-52c9094c6082 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a969c3-1144-4151-9cf3-3e9bace6a380 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd035d0-529c-6033-e053-6294a90abf07 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9deb251-96d3-5f96-e053-2a95a90a0792 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6637d90b-b268-4a5f-ab5b-885f2d5f0d4b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e1cbf26-d379-4315-8732-3939968f32c0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1aa55ec-5e0e-3a58-e053-2a95a90abe4f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f38a6df2-1dd4-48bf-9ec4-1113ce492e78 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f403c94d-68b7-43df-8c8e-c9fef3309cfc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff15c4f1-8869-4422-9631-dc488e09e583 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dce2e97a-cd92-46b9-9444-91739bdcd526 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39ba58cc-e4ef-4b82-a0f3-9583fa123a38 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f0103a-2b97-d210-6d7d-c627d60ad694 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c46140c-2399-5ca3-e063-6394a90af33b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c39be14b-e881-4586-b77e-4747db494954 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9fbf3b5-ddf4-4d3a-8b69-a0c38b3fa5e2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89a5396-1d94-c7fa-e053-2995a90a9063 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:440b9ae8-2fb8-5d35-e063-6294a90a82b6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a94a37-47c1-4dd9-9e4d-5b4a03480aa6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de419aa0-caa9-40fb-bc6d-e341c94273c7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03dea010-4bae-43ab-893e-9bbddb58062d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9daa1483-5a36-44db-9e0d-904d100da262 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
The serum protein binding of pantoprazole is about 98%, primarily to albumin.
Projected row 1172
- Medicine slug
- pantoprazole
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 133
- Source count
- 107
- Agreement rate
- 1
- Recorded readings
2.5 h
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 107
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 107 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58d32be2-166e-1a64-e063-6394a90a26ea (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81696241-17d5-4d35-9e59-8c28469ffd2c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03aa46f-9eb5-4cf4-addf-745d94af8261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4494f9d0-a1c8-477f-9b4a-f65d7637d9ec (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (Cmax) is 2.5 mcg/mL; the time to reach the peak concentration (tmax) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bed1bae-519f-1bb9-e063-6294a90a795b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d212e8ec-f7ff-4727-a83e-0edc4ca7e6d1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643eb498-d916-4fb7-9281-32895575ab36 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e1839b-7462-4344-b319-001a5f57d67a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb1e79ad-ff52-4696-8743-523f793b29d3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f50bcb-85e5-e3f6-e063-6294a90a11ae (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8748a588-a1e5-9dfc-e053-2a95a90a846c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1680b4ed-d5b0-4fd9-b1d1-04df6a2138be (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e5421ef-0875-4a04-b17d-95cca0052c83 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517d6b02-0e68-4d6b-98b3-eac0be457e6b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6faf465b-c3a3-4ae7-9e16-1ba758f6962a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d27e1fdd-e23f-0d60-e053-2a95a90a9087 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (Cmax) is 2.5 µg/mL; the time to reach the peak concentration (tmax) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9b0d279-118b-4372-bd51-d4bad9c1cfca (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3540d01c-da0e-477e-9e90-994b96deb1d6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e200326-8885-18d0-e063-6294a90aad2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed264262-21bb-1bae-e053-2995a90a8a5e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f85e6d64-1ddc-4f4a-86dc-0749081a6a5f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08098cb2-c048-4640-f387-6beec4a38936 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 μg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 μg∙h/mL (range 1.4 to 13.3 μg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c286e5c-2b36-422b-9f74-e8c0abb3f747 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cc5197e-6b39-4415-b963-d4bbeecd7953 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17468dbf-84b6-4c53-9ad5-341350d2cfab (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56ad5b97-8e5f-48a5-b2ba-a5484b43d018 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a278de-bd16-417c-a741-81bfe0d745f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e7c1ab-3e75-1ff8-e053-2995a90a7539 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (Cmax) is 2.5 mcg/mL; the time to reach the peak concentration (tmax) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b422c5eb-9a6d-4f8c-863d-ca515ec780c2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7418f358-f536-4de6-adf0-562b4373f2e3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f2fb647-15bc-41cb-84a4-02e956e614fc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:138b30cb-6b28-450e-9e7a-42576cc76545 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fbec80c-b38d-122c-e054-00144ff88e88 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9f32edf-e0b9-4e96-e053-2a95a90afbc8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4136d983-75fa-9604-e063-6294a90aaac6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9fa8381-b75e-b1cd-e053-2a95a90a9883 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a1af50-a051-3e55-e053-2a95a90a9184 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5ed424-2203-482f-bb85-2c97d9c356f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:564709e8-358f-c185-4ecb-b3849c3fe59c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbab54-9f11-77bc-e063-6394a90ab449 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5566b4b1-b4f5-4020-e063-6394a90a5257 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a8fa326-ad75-4b6d-8832-0a2357eeca2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a6b13f-457f-4136-9541-c4adb9c3c35c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9bc288b-e84c-4e31-a769-c87a59226086 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410d5577-e50a-44f3-aaa8-fbf391a0c261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51033ddc-a11a-80fa-e063-6394a90ac54c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549da3e8-f223-2ee7-e063-6394a90a25d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0bb76bc-094a-4d61-9bb2-2226c9da4ae9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 μg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 μg•h/mL (range 1.4 to 13.3 μg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e17e4a72-d6a4-4a83-a921-88af9ef028a6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd4759ac-46b5-6903-e053-2a95a90a6319 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max) is 2.5 mcg/mL; the time to reach the peak concentration (t max) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924a80b9-de48-90c0-e053-2995a90a00e1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423dac8b-bb1e-4456-9b6e-913c028b11bc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c9e3c6-d4b0-0ebe-e053-2995a90abe55 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max) is 2.5 mcg/mL; the time to reach the peak concentration (t max) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ff83f9-7039-ac26-e063-6394a90a37ce (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90963a38-f629-45a4-bddd-9e13a55fe0f7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da67e1c0-9947-957d-e053-2a95a90ad96d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a1159d3-b9fa-4026-962c-d3001002e610 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:558dc7e1-dfd5-d3d7-e063-6394a90ab9c3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c14e2f3-625d-4089-a404-440b0ecf72e7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ff3cf6c-6f0a-4374-8b80-4e1eb1df6245 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6aae78e-308b-7072-e053-2a95a90aaa10 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1eb666a-120d-47fd-8c9f-73cef839294a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7705bf6-e473-4b9c-bb5d-57e26ffe7b97 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aac1642-6cb0-6ad2-e053-2a95a90a4cbd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43fc6326-cfe6-7d1c-e063-6394a90abc24 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6229247e-ee15-466e-a8ac-adcd646b738d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c983da1-a8e0-479e-8816-5d5668ea242e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1f37929-a981-4ace-95e6-ae6795a797b3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f313159c-115a-4cf6-b32e-9ddc833fd51c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3ded82a-cf0d-4844-944a-75f9f9215ff0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485212d4-caee-4a55-8299-87a28d6bd8f0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee6278c0-d8c0-417c-a65c-b522ff76fe44 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f711d8-b9d3-46a6-8bf9-6af1cc77003e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f408cf-1b3e-4d7a-e053-2a95a90a369f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cec41e-e98b-470a-8ba2-c31537023989 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcac4022-fea1-67c5-3331-fefcc3c440d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa8eed8c-f5d0-4b90-b184-cff8d9c8fb6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5331f534-4724-52e8-e063-6394a90aa548 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58c376e-616b-4970-a375-52ff630e7f09 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d03491f-20c6-4878-9741-2e21e221eff2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d51104d-b135-421f-8425-03b5772e7103 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c10e9c12-e39d-4b0b-bd4c-10d3e9a4cf34 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7dc4321-331d-49af-976c-cfd69d0055d9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38353b9e-63bd-47e8-b7cb-b198d1e901f9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2abc159-e450-99dc-e053-2a95a90abe6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:617bb464-5357-472f-8e9d-61aae5b2ebef (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3277cb8-26d0-bce0-e053-2a95a90af6dd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (Cmax) is 2.5 mcg/mL; the time to reach the peak concentration (tmax) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a969c3-1144-4151-9cf3-3e9bace6a380 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg∙h/mL (range 1.4 to 13.3 mcg∙h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd035d0-529c-6033-e053-6294a90abf07 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9deb251-96d3-5f96-e053-2a95a90a0792 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6637d90b-b268-4a5f-ab5b-885f2d5f0d4b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e1cbf26-d379-4315-8732-3939968f32c0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 µg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 µg•h/mL (range 1.4 to 13.3 µg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1aa55ec-5e0e-3a58-e053-2a95a90abe4f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f38a6df2-1dd4-48bf-9ec4-1113ce492e78 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f403c94d-68b7-43df-8c8e-c9fef3309cfc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff15c4f1-8869-4422-9631-dc488e09e583 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dce2e97a-cd92-46b9-9444-91739bdcd526 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39ba58cc-e4ef-4b82-a0f3-9583fa123a38 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f0103a-2b97-d210-6d7d-c627d60ad694 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c46140c-2399-5ca3-e063-6394a90af33b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9fbf3b5-ddf4-4d3a-8b69-a0c38b3fa5e2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89a5396-1d94-c7fa-e053-2995a90a9063 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max) is 2.5 mcg/mL; the time to reach the peak concentration (t max) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:440b9ae8-2fb8-5d35-e063-6294a90a82b6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a94a37-47c1-4dd9-9e4d-5b4a03480aa6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de419aa0-caa9-40fb-bc6d-e341c94273c7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03dea010-4bae-43ab-893e-9bbddb58062d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9daa1483-5a36-44db-9e0d-904d100da262 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
In extensive metabolizers with normal liver function receiving an oral dose of the enteric-coated 40 mg pantoprazole tablet, the peak concentration (C max ) is 2.5 mcg/mL; the time to reach the peak concentration (t max ) is 2.5 h, and the mean total area under the plasma concentration versus time curve (AUC) is 4.8 mcg•h/mL (range 1.4 to 13.3 mcg•h/mL).
Projected row 1173
- Medicine slug
- pantoprazole
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 133
- Source count
- 133
- Agreement rate
- 0.556391
- Recorded readings
11 to 23.6 L
- Numeric value
- 11
- Unit
- L
- Source records
- 74
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 74 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58d32be2-166e-1a64-e063-6394a90a26ea (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9e5fac6-2db6-4311-a98b-eb3f0dde19d6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:340b57c2-bcf8-4f46-b522-886daaf80351 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb3f58d4-0c69-4377-be45-c36099c98d33 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e1839b-7462-4344-b319-001a5f57d67a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8748a588-a1e5-9dfc-e053-2a95a90a846c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1680b4ed-d5b0-4fd9-b1d1-04df6a2138be (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e5421ef-0875-4a04-b17d-95cca0052c83 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:517d6b02-0e68-4d6b-98b3-eac0be457e6b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1172bc4e-1700-402f-8262-97f05bac0d09 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02ee7ed6-217f-4128-bbbb-b9390475a65b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e200326-8885-18d0-e063-6294a90aad2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cc5197e-6b39-4415-b963-d4bbeecd7953 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50a278de-bd16-417c-a741-81bfe0d745f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7e7c1ab-3e75-1ff8-e053-2995a90a7539 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52d5bc28-66df-43aa-bb1a-8ac4a2a7f693 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:014f9762-6948-46b7-8659-5c89f35ad8bf (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b422c5eb-9a6d-4f8c-863d-ca515ec780c2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0696b10c-972b-9dcf-e063-6294a90a1034 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7418f358-f536-4de6-adf0-562b4373f2e3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f2fb647-15bc-41cb-84a4-02e956e614fc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:138b30cb-6b28-450e-9e7a-42576cc76545 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50802e19-72d3-4130-8d14-eb94361b38e7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e102c44-232b-4aaf-b457-2a740c47193a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9f32edf-e0b9-4e96-e053-2a95a90afbc8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13c337e7-1e7b-47bd-9f88-92b0d548ca9c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b9fa8381-b75e-b1cd-e053-2a95a90a9883 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f39b3e7d-39d2-4c8a-9974-4ab885241880 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a1af50-a051-3e55-e053-2a95a90a9184 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bbab54-9f11-77bc-e063-6394a90ab449 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5566b4b1-b4f5-4020-e063-6394a90a5257 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c857dc41-7b47-4f26-a9f5-d76eb82b44ee (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1bb94d3c-8bc3-4193-9dd8-e9a22066707c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02f3f85-8f9b-4d06-8eae-73e592626f3e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3cde88e6-28f2-4cbe-8c3f-770b05cc0e1b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91a6b13f-457f-4136-9541-c4adb9c3c35c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4ba4c797-3f97-4d85-971e-7b17bdf89221 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:410d5577-e50a-44f3-aaa8-fbf391a0c261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:924a80b9-de48-90c0-e053-2995a90a00e1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9fcf6a2-3788-4955-84d9-3c319b13267c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:362229c5-7b28-4563-aa62-d97d06005480 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51e4144a-489e-436c-609a-39305f8f56ba (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22b71a1d-87f8-43ba-b53d-53ca3f70c63e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e0c5dac-6832-4692-b012-ca59d5e88987 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a1159d3-b9fa-4026-962c-d3001002e610 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:558dc7e1-dfd5-d3d7-e063-6394a90ab9c3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bed093a-9586-4c82-a2b7-c68f89d0faef (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ff3cf6c-6f0a-4374-8b80-4e1eb1df6245 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1ad8f91-3783-4139-8154-e461a53809c1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6aae78e-308b-7072-e053-2a95a90aaa10 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1eb666a-120d-47fd-8c9f-73cef839294a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7705bf6-e473-4b9c-bb5d-57e26ffe7b97 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8aac1642-6cb0-6ad2-e053-2a95a90a4cbd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6229247e-ee15-466e-a8ac-adcd646b738d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f313159c-115a-4cf6-b32e-9ddc833fd51c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:485212d4-caee-4a55-8299-87a28d6bd8f0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f408cf-1b3e-4d7a-e053-2a95a90a369f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcac4022-fea1-67c5-3331-fefcc3c440d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5331f534-4724-52e8-e063-6394a90aa548 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6d03491f-20c6-4878-9741-2e21e221eff2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7dc4321-331d-49af-976c-cfd69d0055d9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b2abc159-e450-99dc-e053-2a95a90abe6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c18aff31-f91e-4b6a-9713-52c9094c6082 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42a969c3-1144-4151-9cf3-3e9bace6a380 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9deb251-96d3-5f96-e053-2a95a90a0792 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6637d90b-b268-4a5f-ab5b-885f2d5f0d4b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f38a6df2-1dd4-48bf-9ec4-1113ce492e78 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f403c94d-68b7-43df-8c8e-c9fef3309cfc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dce2e97a-cd92-46b9-9444-91739bdcd526 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c46140c-2399-5ca3-e063-6394a90af33b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c39be14b-e881-4586-b77e-4747db494954 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11 to 23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9fbf3b5-ddf4-4d3a-8b69-a0c38b3fa5e2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de419aa0-caa9-40fb-bc6d-e341c94273c7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03dea010-4bae-43ab-893e-9bbddb58062d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14 L/h, and its apparent volume of distribution is 11 to 23.6 L.
11.0 to 23.6 L
- Numeric value
- 11
- Unit
- L
- Source records
- 57
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 57 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81696241-17d5-4d35-9e59-8c28469ffd2c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a03aa46f-9eb5-4cf4-addf-745d94af8261 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11.0-23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4494f9d0-a1c8-477f-9b4a-f65d7637d9ec (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bed1bae-519f-1bb9-e063-6294a90a795b (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d212e8ec-f7ff-4727-a83e-0edc4ca7e6d1 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:643eb498-d916-4fb7-9281-32895575ab36 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb1e79ad-ff52-4696-8743-523f793b29d3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f50bcb-85e5-e3f6-e063-6294a90a11ae (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6faf465b-c3a3-4ae7-9e16-1ba758f6962a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d27e1fdd-e23f-0d60-e053-2a95a90a9087 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9b0d279-118b-4372-bd51-d4bad9c1cfca (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3540d01c-da0e-477e-9e90-994b96deb1d6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed264262-21bb-1bae-e053-2995a90a8a5e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f85e6d64-1ddc-4f4a-86dc-0749081a6a5f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08098cb2-c048-4640-f387-6beec4a38936 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6–14.0 L/h, and its apparent volume of distribution is 11.0–23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c286e5c-2b36-422b-9f74-e8c0abb3f747 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:17468dbf-84b6-4c53-9ad5-341350d2cfab (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56ad5b97-8e5f-48a5-b2ba-a5484b43d018 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4fbec80c-b38d-122c-e054-00144ff88e88 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4136d983-75fa-9604-e063-6294a90aaac6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b5ed424-2203-482f-bb85-2c97d9c356f2 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:564709e8-358f-c185-4ecb-b3849c3fe59c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a8fa326-ad75-4b6d-8832-0a2357eeca2f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9bc288b-e84c-4e31-a769-c87a59226086 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of pantoprazole is approximately 11.0-23.6 L, distributing mainly in extracellular fluid.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51033ddc-a11a-80fa-e063-6394a90ac54c (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549da3e8-f223-2ee7-e063-6394a90a25d8 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0bb76bc-094a-4d61-9bb2-2226c9da4ae9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e17e4a72-d6a4-4a83-a921-88af9ef028a6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd4759ac-46b5-6903-e053-2a95a90a6319 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c9e3c6-d4b0-0ebe-e053-2995a90abe55 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07ff83f9-7039-ac26-e063-6394a90a37ce (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da67e1c0-9947-957d-e053-2a95a90ad96d (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c14e2f3-625d-4089-a404-440b0ecf72e7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43fc6326-cfe6-7d1c-e063-6394a90abc24 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c983da1-a8e0-479e-8816-5d5668ea242e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1f37929-a981-4ace-95e6-ae6795a797b3 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3ded82a-cf0d-4844-944a-75f9f9215ff0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee6278c0-d8c0-417c-a65c-b522ff76fe44 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f711d8-b9d3-46a6-8bf9-6af1cc77003e (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3cec41e-e98b-470a-8ba2-c31537023989 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa8eed8c-f5d0-4b90-b184-cff8d9c8fb6a (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b58c376e-616b-4970-a375-52ff630e7f09 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d51104d-b135-421f-8425-03b5772e7103 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c10e9c12-e39d-4b0b-bd4c-10d3e9a4cf34 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38353b9e-63bd-47e8-b7cb-b198d1e901f9 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:617bb464-5357-472f-8e9d-61aae5b2ebef (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3277cb8-26d0-bce0-e053-2a95a90af6dd (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbd035d0-529c-6033-e053-6294a90abf07 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e1cbf26-d379-4315-8732-3939968f32c0 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6-14.0 L/h, and its apparent volume of distribution is 11.0-23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1aa55ec-5e0e-3a58-e053-2a95a90abe4f (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff15c4f1-8869-4422-9631-dc488e09e583 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39ba58cc-e4ef-4b82-a0f3-9583fa123a38 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:82f0103a-2b97-d210-6d7d-c627d60ad694 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c89a5396-1d94-c7fa-e053-2995a90a9063 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:440b9ae8-2fb8-5d35-e063-6294a90a82b6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a94a37-47c1-4dd9-9e4d-5b4a03480aa6 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9daa1483-5a36-44db-9e0d-904d100da262 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 to 14.0 L/h, and its apparent volume of distribution is 11.0 to 23.6 L.
11.0 L
- Numeric value
- 11
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423dac8b-bb1e-4456-9b6e-913c028b11bc (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 L/h to 14.0 L/h, and its apparent volume of distribution is 11.0 L to 23.6 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90963a38-f629-45a4-bddd-9e13a55fe0f7 (opens source in a new tab)
Pantoprazole label
Version not recorded · Effective date not recorded
Following intravenous administration of pantoprazole to extensive metabolizers, its total clearance is 7.6 L/h to 14.0 L/h, and its apparent volume of distribution is 11.0 L to 23.6 L.
Projected row 1174
- Medicine slug
- paricalcitol
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 16
- Source count
- 16
- Agreement rate
- 0.6875
- Recorded readings
4 to 6 hours
- Numeric value
- 4
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f593b575-7537-4531-87fc-c1b0814fd018 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers,the mean elimination half-life of paricalcitol in CKD Stages 3,4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59738576-3494-4d72-98d2-6904a3778081 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:755476e5-62a2-4f01-92a3-307e192ad42c (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b27c026-2d60-47b4-2a9c-ded1818f21b5 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd937aab-6ed2-44ef-b91e-82738997ed10 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a0d467-9881-458f-8b1c-1186feb96ee4 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:664253fb-d99d-4af6-971b-95c0087406d9 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ca3d88-e85d-44a9-8aa7-eb25a8a73f6f (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa1a80e9-8778-a03e-5d53-d4b6a6363169 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fbaff52-f08f-42b7-8e46-c7214112901a (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers,the mean elimination half-life of paricalcitol in CKD Stages 3,4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d62d977a-bbfc-454a-a4a9-017a9f525574 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
While the mean elimination half-life of paricalcitol is 4 to 6 hours in healthy adult volunteers, the mean elimination half-life of paricalcitol in CKD Stages 3, 4, and 5 (on HD and PD) patients ranged from 14 to 20 hours.
17.0 hours
- Numeric value
- 17
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6937c596-9ca4-480e-9090-b9d8a3c271c8 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
The mean half-life of paricalcitol was 17.0 hours in the presence of ketoconazole as compared to 9.8 hours, when paricalcitol was administered alone [see Drug Interactions (7) ] . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Paricalcitol is a synthetic, biologically active vitamin D 2 analog.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7259652f-81bc-4ad1-bba5-d01f9fac1b80 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
The mean half-life of paricalcitol was 17.0 hours in the presence of ketoconazole as compared to 9.8 hours, when paricalcitol was administered alone [see Drug Interactions ( 7 ) ] . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Paricalcitol is a synthetic, biologically active vitamin D 2 analog.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4db985c4-3ba2-4967-898b-35af77f150de (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
The mean half-life of paricalcitol was 17.0 hours in the presence of ketoconazole as compared to 9.8 hours, when paricalcitol was administered alone [see Drug Interactions ( 7.1 ) ]. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results i
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7c7587-2042-0d9c-e054-00144ff88e88 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
The mean half-life of paricalcitol was 17.0 hours in the presence of ketoconazole as compared to 9.8 hours, when paricalcitol was administered alone [see Drug Interactions (7) ] . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Paricalcitol is a synthetic, biologically active vitamin D 2 analog.
17 hours
- Numeric value
- 17
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e0b016c-4bda-487e-b525-63abfb772761 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
The mean half-life of paricalcitol was 17 hours in the presence of ketoconazole as compared to 9.8 hours, when paricalcitol was administered alone [see Drug Interactions (7) ] . 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Paricalcitol is a synthetic, biologically active vitamin D 2 analog.
Projected row 1175
- Medicine slug
- paricalcitol
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 16
- Agreement rate
- 1
- Recorded readings
99.8%
- Numeric value
- 99.8
- Unit
- %
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f593b575-7537-4531-87fc-c1b0814fd018 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59738576-3494-4d72-98d2-6904a3778081 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6937c596-9ca4-480e-9090-b9d8a3c271c8 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7259652f-81bc-4ad1-bba5-d01f9fac1b80 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4db985c4-3ba2-4967-898b-35af77f150de (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution : Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:755476e5-62a2-4f01-92a3-307e192ad42c (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b27c026-2d60-47b4-2a9c-ded1818f21b5 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd937aab-6ed2-44ef-b91e-82738997ed10 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a0d467-9881-458f-8b1c-1186feb96ee4 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:664253fb-d99d-4af6-971b-95c0087406d9 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ca3d88-e85d-44a9-8aa7-eb25a8a73f6f (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa1a80e9-8778-a03e-5d53-d4b6a6363169 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7c7587-2042-0d9c-e054-00144ff88e88 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fbaff52-f08f-42b7-8e46-c7214112901a (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d62d977a-bbfc-454a-a4a9-017a9f525574 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e0b016c-4bda-487e-b525-63abfb772761 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Distribution Paricalcitol is extensively bound to plasma proteins (≥ 99.8%).
Projected row 1176
- Medicine slug
- paricalcitol
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 11
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f593b575-7537-4531-87fc-c1b0814fd018 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59738576-3494-4d72-98d2-6904a3778081 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:755476e5-62a2-4f01-92a3-307e192ad42c (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b27c026-2d60-47b4-2a9c-ded1818f21b5 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd937aab-6ed2-44ef-b91e-82738997ed10 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a0d467-9881-458f-8b1c-1186feb96ee4 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:664253fb-d99d-4af6-971b-95c0087406d9 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ca3d88-e85d-44a9-8aa7-eb25a8a73f6f (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aa1a80e9-8778-a03e-5d53-d4b6a6363169 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0fbaff52-f08f-42b7-8e46-c7214112901a (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d62d977a-bbfc-454a-a4a9-017a9f525574 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
Food delayed T max by about 2 hours.
Projected row 1177
- Medicine slug
- paricalcitol
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
23.8 L
- Numeric value
- 23.8
- Unit
- L
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6937c596-9ca4-480e-9090-b9d8a3c271c8 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
In healthy subjects, the steady state volume of distribution is approximately 23.8 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7259652f-81bc-4ad1-bba5-d01f9fac1b80 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
In healthy subjects, the steady state volume of distribution is approximately 23.8 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4db985c4-3ba2-4967-898b-35af77f150de (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
In healthy subjects, the steady state volume of distribution is approximately 23.8 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b7c7587-2042-0d9c-e054-00144ff88e88 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
In healthy subjects, the steady-state volume of distribution is approximately 23.8 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e0b016c-4bda-487e-b525-63abfb772761 (opens source in a new tab)
Paricalcitol label
Version not recorded · Effective date not recorded
In healthy subjects, the steady-state volume of distribution is approximately 23.8 L.
Projected row 1178
- Medicine slug
- paroxetine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 92
- Source count
- 89
- Agreement rate
- 0.876404
- Recorded readings
21 hours
- Numeric value
- 21
- Unit
- hours
- Source records
- 78
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 78 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d558598-6905-46da-8f34-668456c68411 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45ef7ce8-5aa0-488c-a81c-cdfbda66ac04 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine hydrochloride daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0acc97d-3d8d-4a7f-8acd-99050b0af2f1 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a809a6b5-18a3-4771-aaf8-7197d1743540 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89dd7e24-85fc-4152-89ea-47ec2b48a1ed (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08320ea3-8f93-6f04-5d1c-f69af3eb5a81 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1ea4019-bb66-403c-a3d5-6ae056a59116 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30fd2fc4-f661-44c9-a9a9-9d0de0892e3c (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:525884d7-e2ee-4d57-a6c9-bd129e9fb9d0 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of Paroxetine Tablets daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65c81817-34d3-4c57-a4bf-fb10be98386d (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91c5a321-e174-4d86-9a84-e5e278d45aff (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34909bfb-b4ad-25c4-e063-6294a90a0296 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69699d40-4a64-4337-8664-e4e093437fbf (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9a5e0aa-e638-5d6e-75c2-20cb78fc4f43 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4abd94c5-5ad5-4a43-9c51-a93ea1c1f3bc (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4acd3e7a-4f19-4428-9452-48ce370cb3db (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b4c469-19b3-44b9-a378-c7c3f4f436db (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40dcf270-64bb-bca0-db08-6b233a3430f8 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:847118ec-c139-466c-834b-1ae0b6e1f791 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8526c68d-221c-4822-9532-1d7868cff35e (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of Paroxetine Tablets daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a8a58c7-5008-4c65-ae0e-e4ee809b1807 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2eebd2b6-7c64-45ca-8eb5-5201137f610a (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine hydrochloride daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc11a056-7db5-1966-e053-6394a90aa59c (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:326e8ab0-6886-4749-9544-885b37070051 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98d4f767-06e3-4d9b-b1ad-4b31f7e36130 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beb87e2e-0a8f-43b6-b148-57f0b7191548 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e176ff2-ed3a-4909-94e1-6b9a3581a621 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec9622ca-1f56-4216-9445-485791c4c0ed (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine hydrochloride daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of PAXIL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49dd0858-685f-f46b-e063-6294a90a7f39 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49dc055c-faef-0be3-e063-6394a90a934f (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31e4bb7c-59ab-4cbf-ba08-317c1417b28f (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26d37a39-1c53-461c-8834-c67fbffcfe99 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e63fe922-b35a-406c-8737-f3f5e6d5a30d (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff7c7e20-c9ee-4693-beaa-7ac532d5c4b7 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6318eefa-ee51-4e4e-91a5-8760d48bdc63 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of paroxetine tablets, 30 mg daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3c204df-6b7d-42fb-8794-4f38064ed963 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fea936a5-fdeb-e4fb-e053-6294a90a8995 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:619e10bb-6e5d-4ec3-a85a-6270965f5389 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54efbbc1-4f5f-262d-e063-6394a90aadbc (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5206418-aa7f-42dd-b977-4b9d1e4b2752 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:009d8b89-eab9-43ba-b077-86bfa993a745 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce168c41-a860-45f5-bae8-7b3d9b48d86a (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of Paroxetine Tablets daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1801246b-02c3-430f-932a-b18cb0d13d1d (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7128be7-7023-40c4-aa64-29d52145ae31 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:134e76f0-45cf-47eb-b6e1-cdb3bb522a0a (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84b1b1f0-d375-4fda-99af-9487f8ef50c7 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d3b4536-7900-223c-e063-6294a90a3d60 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f52ca1fc-fbf7-4b2b-9e74-975c310b8ce6 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:333dfd07-61f0-4b86-b4b5-b04adf64e49f (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:903e4ef1-487d-4b65-9038-b05ceaf74d19 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of Paroxetine Tablets daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25182b68-8f7a-48e8-9788-6818b0984b29 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07f245c5-fcb0-3008-d69e-10290cadbfa6 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a0f8897-2099-4038-9b96-ed9c4f084018 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4cb9dc05-adb8-4c88-ad40-af8c0df1cafd (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:679e4b9b-0f7b-450a-aca7-1b448cccbeed (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee38b589-e646-4203-bea5-cc3744fe17c3 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:605c1d23-c97c-4ea4-92d0-fed351de9d2e (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c002508e-f96c-413b-b232-5d55fceeffe0 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:570a9f0d-04fb-2922-e054-00144ff88e88 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of paroxetine tablets, 30 mg daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6bb4f0a-1555-4550-a7a4-99609674b1e7 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:90c129a8-afce-4b8b-85d7-f89e6da2aef7 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3b2ce88-6f09-4f7b-ac73-93dca84aa3b8 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of Paroxetine Tablets daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:598ece4d-0ac4-993b-e063-6294a90a1d34 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:598efb76-93ef-f7de-e063-6394a90a632e (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6cfde064-ddcb-49df-a53c-953c40eb1470 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a702760-9b72-4595-bf47-01aff786c74d (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cfe30fc-9c46-4efd-e054-00144ff8d46c (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of paroxetine tablets, 30 mg daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5a8f864-a53d-48d9-aca6-6b64017fb168 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28ddc9e0-05c5-482f-9371-60bbee451b33 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22174520-4b78-4841-96f7-530ba12d2cf1 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05ec70fd-4c65-495f-ba12-e8433a10b655 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:118320de-0632-4139-8b13-7428b41da0ac (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc0efd3b-c6b9-4ed0-b517-6e57e4700b7b (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d551f3d0-9503-45bd-b701-dfed4c8a5e1e (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:662223ec-3b9b-4a85-9680-789522363a7b (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac6ea24f-a9f3-4413-8c3a-9e2e4ca93c0f (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of Paroxetine Tablets daily for 30 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b2e6cd0-d779-4b7b-b3aa-85b796874ac3 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine tablets.
15 to 20 hours
- Numeric value
- 15
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:087ff0d3-1761-47ea-a8c1-7c4cb679af97 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of Paroxetine HCL CR (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d315e0da-f829-408b-be5d-2bca2e06913c (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of paroxetine extended-release tablets (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:555cfa31-3865-450f-b16b-2f4004af7a67 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of paroxetine extended-release tablets (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59cb7de6-483d-4007-b6ef-f10a70b872e9 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of paroxetine extended-release tablets (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e43cdbd-2419-434b-96b9-920f02558d1c (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of paroxetine extended-release tablets (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52c3c5c4-6434-4f95-b5f0-9ecfdc0a7e0a (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of Paroxetine (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:483bd97f-c4d0-4e23-aaa8-6334f4471e0c (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of PAXIL CR (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f22886f5-230c-47e4-9dd8-ffb14c8d6ae4 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of Paroxetine (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e47c4fb-6070-4cb4-acaa-c6e90199b55c (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of Paroxetine (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5da839f9-e2bf-4b83-a410-1226ba4552a1 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of paroxetine extended-release tablets (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f39a2a7a-7a7e-4dd8-9704-54d9598504fb (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Elimination Metabolism The mean elimination half-life of paroxetine was 15 to 20 hours throughout a range of single doses of paroxetine extended-release tablets (12.5 mg, 25 mg, 37.5 mg, and 50 mg).
Projected row 1179
- Medicine slug
- paroxetine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 92
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1383d713-79b9-45bd-bd06-65707f28bc99 (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Peak concentrations were reached at a median of 6 hours (3 to 8 hours range).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:502311b3-b617-4cbd-a3ab-a60f2c62880a (opens source in a new tab)
Paroxetine label
Version not recorded · Effective date not recorded
Peak concentrations were reached at a median of 6 hours (3 to 8 hours range).
Projected row 1180
- Medicine slug
- pazopanib
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 1
- Recorded readings
31 hours
- Numeric value
- 31
- Unit
- hours
- Source records
- 9
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 9 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:115eb5bb-1403-fb3d-e063-6394a90ad320 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f7ea520-a152-401e-b1f7-b5ef8c7a2239 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16c5df52-0031-034d-e063-6294a90a1717 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b05ea49a-a764-5ff2-6e4a-26add69da9e2 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3e8dd09-d7d2-43da-8f63-bdf0ea0fcdf5 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25575cc6-5757-4f9b-9c09-0c4deb61ba12 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeaaaf38-fb86-4d9f-a19d-0f61daac2fd7 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7235fad0-eb5b-4fdf-a362-c8c65c9bfe1d (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25305d33-caa0-4577-8b7b-06e430c34c39 (opens source in a new tab)
Pazopanib label
Version not recorded · Effective date not recorded
Elimination Pazopanib has a mean half-life of 31 hours after administration of the recommended dose of 800 mg.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1170Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.